newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has signed an agreement with an